pediatric cancer

This embargo-free strategy represents "an entirely new way of doing research" into rare pediatric cancers, where time is of the essence.

DNA sequence data from 416 neuroblastoma cases led to informative alterations affecting genes from telomere maintenance, RAS, or TP53 pathways.

A common variant polygenic risk score, rare cancer risk gene mutations, and prior treatments each provide clues to breast cancer risk in childhood cancer survivors.

The UK-based maker of clinical genomics interpretation software is moving into the US and China after carefully researching the differences from European markets.

Canada's Gene42, maker of PhenoTips software, recently forged partnerships with CHOP, Genome Canada, and SeqOne in the fight against rare genetic diseases.

Researchers found that the diverse features in mixed phenotype acute leukemia may stem from early blood progenitor mutations.

CHOP's Gabriella Miller Kids First Pediatric Data Resource Center will use PhenoTips software from Gene42 to integrate "deep phenotyping" with genomic data.

Researchers uncovered subclones within pediatric glioblastoma and diffuse intrinsic pontine glioma patients that influence the abilities of neighboring cells.

St. Jude researchers found germline mutations in the transcription factor gene IKZF1 in 0.9 percent of presumed sporadic pediatric acute lymphoblastic leukemia cases.

The national PROFYLE study seeks to sequence tumor and matched normal samples from children and young adults with relapsed or treatment-resistant cancer.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.